Welcome to our dedicated page for Lineage Cell The SEC filings (Ticker: LCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the clinical progress of Lineage Cell Therapeutics means navigating pages of stem-cell science, trial protocols, and partnership footnotes. Locating when an executive exercises options or how much was spent on pluripotent cell manufacturing can feel overwhelming.
Our platform turns that complexity into clarity. Each Lineage Cell Therapeutics quarterly earnings report 10-Q filing is paired with AI-powered summaries that spotlight R&D burn, cash runway, and upcoming clinical milestones. The latest Lineage Cell Therapeutics annual report 10-K simplified section breaks down pipeline risks, market opportunities in age-related macular degeneration, and manufacturing scale-up costs鈥攏o biotech PhD required.
Need real-time sentiment? Receive instant alerts on Lineage Cell Therapeutics insider trading Form 4 transactions. Our system flags every Lineage Cell Therapeutics Form 4 insider transactions real-time, so you see when scientists or directors buy shares before pivotal read-outs. Material updates land here the moment an 8-K material events explained notice hits EDGAR, while the proxy statement executive compensation section decodes option grants tied to clinical success.
- AI summaries that answer 鈥渦nderstanding Lineage Cell Therapeutics SEC documents with AI鈥�.
- Automatic tagging of Lineage Cell Therapeutics earnings report filing analysis for easy YoY comparisons.
- Comprehensive coverage of S-3, 424B5 and other financing filings relevant to cell-therapy pipelines.
Whether you鈥檙e scanning a Lineage Cell Therapeutics 10-K for GMP manufacturing costs or checking a Lineage Cell Therapeutics 8-K on trial data, Stock Titan delivers every disclosure鈥攁lready distilled, searchable, and ready for decisive action.
Lineage Cell Therapeutics reported stronger collaboration revenue and continued clinical progress while remaining a development-stage biotech with ongoing operating losses. Total revenues for the six months ended June 30, 2025 were $4.27 million, up from $2.85 million a year earlier, driven primarily by recognized collaboration upfront license fees. Cash and marketable securities totaled approximately $42.3 million at June 30, 2025 and management states these resources, together with available ATM capacity, are expected to fund planned operations for at least twelve months.
Operating results reflect continued R&D and G&A spending and a non-cash $14.84 million impairment of an acquired intangible asset, producing a net loss attributable to Lineage of $34.6 million for the six months. Balance sheet highlights include total assets of $90.8 million, warrant liabilities of $18.8 million (up from $6.2 million), and shareholders' equity of $47.1 million. Clinically, OpRegen showed sustained 36-month visual acuity gains in a subgroup (mean +9.0 ETDRS letters, n=5), OpRegen retains RMAT designation, and the OPC1 DOSED study has been initiated with the first chronic SCI patient treated.
On August 12, 2025, Lineage Cell Therapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025, which is provided as Exhibit 99.1. The Form 8-K states the information is being furnished, not filed, and therefore is not incorporated by reference into other filings. The filing also includes an Inline XBRL cover page as Exhibit 104. The report is signed by George A. Samuel III, General Counsel and Corporate Secretary.
FAQ
What is the current stock price of Lineage Cell The (LCTX)?
What is the market cap of Lineage Cell The (LCTX)?
